ADMINISTRATION
Person with PH1*
*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.
OXLUMO® (lumasiran) is a subcutaneous injection dosed by weight1
Administered via subcutaneous injection by a healthcare professional1
3 monthly starting doses aim to reduce oxalate levels1
Ongoing dosing beginning one month after the last
starting dose aims to sustain the reduction1
Ongoing dosing of OXLUMO is quarterly or monthly
With a dosing regimen designed for PH1 management, OXLUMO is administered monthly for the first 4 months of treatment. After month 4, dosing is available quarterly for patients who weigh ≥10 kg or monthly for patients who weigh <10 kg.
3 starting doses: 3 mg/kg administered monthly
Start
Month 1
Month 2
Ongoing dosing: 3 mg/kg administered quarterly beginning one month after the last starting dose
Month 3
Month 4
Month 5
Month 6
Ongoing quarterly dosing continues past month 6
Download the Dosing Guide3 starting doses: 6 mg/kg administered monthly
Start
Month 1
Month 2
Ongoing dosing: 6 mg/kg administered quarterly beginning one month after the last starting dose
Month 3
Month 4
Month 5
Month 6
Ongoing quarterly dosing continues past month 6
Download the Dosing Guide3 starting doses: 6 mg/kg administered monthly
Start
Month 1
Month 2
Ongoing dosing: 3 mg/kg administered monthly beginning one month after the last starting dose
Month 3
Month 4
Month 5
Month 6
Ongoing monthly dosing continues past month 6
Download the Dosing GuideIf your patient misses a dose
If a dose is delayed or missed, administer OXLUMO as soon as possible and resume prescribed regimen from the most recently administered dose.1
OXLUMO Administration
- Administered via subcutaneous injection by a healthcare professional1
-
- Some patients may qualify to receive the injection at home from a healthcare professional, depending on their insurance coverage
- No dose adjustment is necessary in patients with renal impairment, including kidney failure, or those on hemodialysis
For patients on hemodialysis, administer OXLUMO following hemodialysis if administered on dialysis days.
See full Prescribing Information for detailed steps on how to prepare and administer OXLUMO.
WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?
Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Alnylam Assist® provides support services for patients throughout their treatment with OXLUMO.
Alnylam Assist® includes patient services in 4 key areas, including understanding insurance benefits and financial assistance options for eligible patients,* helping ensure access to therapy, and providing PH1 disease education.
Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
1. OXLUMO [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc.